EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study

Hideto Kameda, Jiayi Dong, Chie Yamamoto, Ayako Konomi, Yumiko Nishikawa, Tetsuya Tomita

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf108 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hideto Kameda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Spondylitis, Ankylosing, Axial Spondyloarthritis, Antirheumatic Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the long-term safety and effectiveness of ixekizumab for axial spondyloarthritis in the real-world setting in Japan.

Methods

This single-arm, multicentre, observational study was conducted from 26 May 2020 to 10 March 2023 on adult patients with axial spondyloarthritis who were administered ixekizumab under daily clinical practice in Japan. Baseline patient characteristics were summarized. Adverse events, adverse drug reactions, physician-rated overall improvement, and patient-reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were assessed for 96 weeks after ixekizumab initiation.

Results

Of the 39 enrolled patients, 29 consented to publication and were included in these analyses (n = 21 ankylosing spondylitis; n = 8 non-radiographic axial spondyloarthritis). Sixteen patients (55.2%) were male, with a median (range) age of 52.0 (32.0–76.0) years. Fourteen (48.3%) and 4 (13.8%) patients experienced adverse events and adverse drug reactions, respectively, most commonly infections and administration site reactions. No serious adverse events or adverse drug reactions were reported. Across 96 weeks, physicians rated ≥75.0% patients as showing improvement. BASDAI scores showed trends consistent with improvement.

Conclusions

These findings are consistent with ixekizumab clinical trial data from other countries, showing the long-term safety and effectiveness of ixekizumab in patients with axial spondyloarthritis under routine clinical care in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSpondylitis, AnkylosingAxial SpondyloarthritisAntirheumatic AgentsHumansMaleFemaleAdultMiddle AgedJapanProduct Surveillance, PostmarketingAgedTreatment OutcomeSeverity of Illness IndexEast Asian People

Stichwörter der Autor:innen

Ankylosing spondylitisJapaneseixekizumabnon-radiographic axial spondyloarthritispost-marketing surveillance

Substanzen

ixekizumabAntibodies, Monoclonal, HumanizedAntirheumatic Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
  • Graduate School of Health Science, Morinomiya University of Medical Sciences, Osaka, Japan.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Kameda, H., Dong, J., Yamamoto, C., Konomi, A., Nishikawa, Y., & Tomita, T. (2025). Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf108

Vancouver

Kameda H, Dong J, Yamamoto C, Konomi A, Nishikawa Y, Tomita T. Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf108

BibTeX
@article{Kameda2025,
  author = {Kameda, Hideto and Dong, Jiayi and Yamamoto, Chie and Konomi, Ayako and Nishikawa, Yumiko and Tomita, Tetsuya},
  title = {Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf108}
}
Kostenlos starten →